Stockscreener 앱 받기
24.28
0.71%
0.17
시간 외 거래:
24.22
-0.06
-0.25%
Septerna Inc 주식(SEPN)의 최신 뉴스
Septerna (SEPN) Expected to Announce Earnings on Thursday - MarketBeat
Layoff Watch: Will Septerna Inc outperform the market in YEARTrade Entry Report & Long-Term Safe Investment Ideas - baoquankhu1.vn
Septerna (SEPN) Is Down 13.5% After Launching US$150 Million ATM Equity Program and Filing Shelves - simplywall.st
Checkpoint Capital L.P. Trims Stock Position in Septerna, Inc. $SEPN - MarketBeat
Avoro Capital Advisors LLC Grows Stock Holdings in Septerna, Inc. $SEPN - MarketBeat
Septerna (NASDAQ:SEPN) Rating Lowered to "Hold" at Wall Street Zen - MarketBeat
HC Wainwright Has Negative Outlook for Septerna Q1 Earnings - MarketBeat
What is HC Wainwright's Forecast for Septerna Q1 Earnings? - MarketBeat
Analysts Conflicted on These Technology Names: Fortinet (FTNT), Septerna, Inc. (SEPN) and Oracle (ORCL) - The Globe and Mail
Truist Financial Forecasts Strong Price Appreciation for Septerna (NASDAQ:SEPN) Stock - MarketBeat
Septerna (SEPN) Q4 Loss Despite Revenue Surge Reinforces Bearish Profitability Narrative - simplywall.st
Wells Fargo Reaffirms Their Buy Rating on Septerna, Inc. (SEPN) - The Globe and Mail
Truist Lifts Price Target on Septerna to $35 From $34, Keeps Buy Rating - marketscreener.com
Cantor Fitzgerald Maintains Overweight on Septerna, Inc. (SEPN) March 2026 - Meyka
Truist raises Septerna stock price target to $35 on trial progress - Investing.com
Cantor Fitzgerald reiterates Septerna stock rating on platform value By Investing.com - Investing.com Australia
Cantor Fitzgerald reiterates Septerna stock rating on platform value - Investing.com
Septerna (SEPN) Reports Narrower Q4 Loss of $0.24/Share as Revenue Climbs to $24.1M - AlphaStreet
Septerna beats fourth quarter loss estimates on collaboration revenue By Investing.com - Investing.com India
Septerna beats fourth quarter loss estimates on collaboration revenue - Investing.com
Decoding Septerna Inc (SEPN): A Strategic SWOT Insight - GuruFocus
Septerna, Inc. (SEPN) Reports Q4 Loss, Tops Revenue Estimates - Bitget
Septerna Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2025 Financial Results - Bitget
Earnings Flash (SEPN) Septerna Posts Q4 Loss $-0.24, vs. FactSet Est of Loss of $-0.24 - marketscreener.com
Biotech firm Septerna beats Q4 revenue expectations, net loss narrows - TradingView
Earnings Summary: Septerna Q4 - Benzinga
Septerna, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
SEPN: Pipeline advances and improved financials set stage for clinical milestones in 2026 - TradingView
Earnings Flash (SEPN) Septerna, Inc. Reports Q4 Revenue $24.1M, vs. FactSet Est of $18.2M - marketscreener.com
SEPN SEC FilingsSepterna, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
How Investors May Respond To Septerna (SEPN) Advancing SEP-631 Into Phase 2b Urticaria Trials - simplywall.st
Can Septerna Inc. stock hit record highs againEarnings Performance Report & Fast Exit Strategy with Risk Control - Naître et grandir
Insider Selling: Septerna (NASDAQ:SEPN) Insider Sells 70,453 Shares of Stock - MarketBeat
Septerna (SEPN) CPO exercises options, then sells 70,453 shares - Stock Titan
Septerna Executive Sells Shares - TradingView
SEPN: SEP-631 advances to phase II in CSU after robust phase I results; SEP-479 enters clinical trials - TradingView
SEPN: SEP-631 and SEP-479 advance with strong data, phase 2 and 1 trials planned, and pipeline growth - TradingView
Analysts Offer Insights on Technology Companies: Septerna, Inc. (SEPN), Payoneer (PAYO) and Porch Group (PRCH) - The Globe and Mail
Septerna Stock: A Deep Dive Into Analyst Perspectives (5 Ratings) - Sahm
A Look At Septerna (SEPN) Valuation After Recent Share Price Momentum And GPCR Pipeline Reassessment - Sahm
Septerna (SEPN) Receives Overweight Rating and Target Price Hike by Wells Fargo | SEPN Stock News - GuruFocus
Wells Fargo & Company Increases Septerna (NASDAQ:SEPN) Price Target to $48.00 - MarketBeat
Does SEP-631’s Phase 1 Proof-of-Mechanism and 2026 Trial Plan Reshape Septerna’s Mast Cell Strategy (SEPN)? - Yahoo Finance
[144] Septerna, Inc. SEC Filing - Stock Titan
Septerna (NASDAQ:SEPN) Price Target Raised to $40.00 at HC Wainwright - MarketBeat
Septerna Advances SEP-631 After Positive Phase 1 Results - TipRanks
SEPN: SEP-631 showed strong Phase 1 efficacy and safety, advancing to Phase 2 for urticaria in 2026 - TradingView
Septerna reports positive Phase 1 SEP-631 data; plans Phase 2b CSU study in 2H 2026 - TradingView
Positive SEP-631 trial data drives Phase 2 plan at Septerna (NASDAQ: SEPN) - Stock Titan
Septerna’s SEP-631 shows positive Phase 1 trial results - Investing.com Australia
Septerna’s SEP-631 shows positive Phase 1 trial results By Investing.com - Investing.com South Africa
Septerna Announces Positive Phase 1 Data for SEP-631, an Oral MRGPRX2 NAM for the Treatment of Mast Cell-Driven Diseases, and Outlines Initial Phase 2 Development Strategy - Bitget
1.20%
0.06%
자본화:
|
볼륨(24시간):